Vanda Pharmaceuticals is a biopharmaceutical company that develops and commercializes innovative therapies for the treatment of central nervous system (CNS) disorders. The company's products include Fanapt, a treatment for schizophrenia, and Hetlioz, a treatment for non-24-hour sleep-wake disorder. Vanda Pharmaceuticals was founded in 2002 by Mihael H. Polymeropoulos and Argeris N. Karabelas and is headquartered in Washington, D.C. The company is committed to improving the lives of patients with CNS disorders through the development of novel therapies and the advancement of scientific research.